ArticleTranslational cancer research2022
MiR-193b as an effective biomarker in human cancer prognosis for Asian patients: a meta-analysis.
Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Myogenic differentiation-derived small extracellular vesicles as a therapeutic strategy for miR-193b-3p-mediated muscle regeneration.Molecular therapy. Nucleic acids · 2026Article
- Updates on the role of miR-193b in the pathogenesis of human cancers and other diseases.Biochemistry and biophysics reports · 2026Review
- Article
- Bee Pollen Phytochemicals and Nutrients as Unequaled Pool of Epigenetic Regulators: Implications for Age-Related Diseases.Foods (Basel, Switzerland) · 2025Review
- Article
- Utilization of miRNAs as Biomarkers for the Diagnosis, Prognosis, and Metastasis in Gynecological Malignancies.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: MiR-193b has been widely investigated in the last few years and an aberrant association has been observed between its expression levels and the prognosis of several human malignancies. We performed a meta-analysis to evaluate the prognostic effect of miR-193b on human cancers. Methods: PMC, PubMed, Web of Science (WOS), Embase in English and VIP, Wanfang, SinoMed and the China National Knowledge Infrastructure (CNKI) in Chinese were searched up to May 16, 2020. The pooled hazard ratio (HR) with a 95% confidence interval (CI) was calculated to evaluate its prognosis in human cancers. Also, the pooled odd ratios and the relevant 95% CIs were computed to assess the association of miR-193b levels and clinicopathological characteristics of cancer patients. Results: In overall analysis, a significant association was identified between miR-193b levels and overall survival (HR =0.77, 95% CI: 0.64-0.92), but this association was not significant in the random pooling model. Then, two outliers were identified through sensitivity analysis. After removing outliers, the significant association was identified with random pooling model (HR =0.45, 95% CI: 0.30-0.69). In addition, the significance exited among Asian (HR =0.45, 95% CI: 0.28-0.74), studies with the sample size (≥100) (HR =0.39, 95% CI: 0.27-0.56) and sample size (<100) (HR =0.51, 95% CI: 0.28-0.92), Newcastle-Ottawa scale (NOS) scores (≥8) (HR =0.44, 95% CI: 0.30-0.67) and NOS scores (<8) (HR =0.45, 95% CI: 0.25-0.80) and patients of non-digestive carcinoma (HR =0.35, 95% CI: 0.24-0.52), digestive carcinoma (HR =0.54, 95% CI: 0.31-0.92), non-urogenital carcinoma (HR =0.52, 95% CI: 0.33-0.82) or urogenital carcinoma (HR =0.28, 95% CI: 0.16-0.50). Lower expression of miR-193b was found to be related to larger tumor size and the potential of lymph node metastasis and distance metastasis. Discussion: We have demonstrated that miR-193b serves as an ideal biomarker in the cancer prognosis for Asian patients, and the low expression levels of miR-193b is significantly associated with poor overall survival rates in various human malignancies. Moreover, the patients with lower miR-193b tend to develop the cancers with higher potential of metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.